Cargando…

Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure()

Detalles Bibliográficos
Autores principales:	Kow, C.S., Ramachandram, D.S., Hasan, S.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801774/ https://www.ncbi.nlm.nih.gov/pubmed/35105515 http://dx.doi.org/10.1016/j.rceng.2021.11.002

Ejemplares similares

Tratamiento con glucocorticoides en pacientes con COVID-19 e insuficiencia cardíaca concurrente
por: Kow, C.S., et al.
Publicado: (2022)

Answer to the “Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure” correspondence()
por: Salinas-Botrán, A., et al.
Publicado: (2022)

Coenzyme Q10 therapy in patients with post COVID-19 condition
por: Kow, Chia Siang, et al.
Publicado: (2023)

Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies
por: Kow, Chia Siang, et al.
Publicado: (2023)

How to make the best of NLRP3 inhibitors in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2023)

Hypertension and severe COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis
por: Kow, Chia Siang, et al.
Publicado: (2020)

Insulin therapy in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

Metformin therapy in COVID-19: inhibition of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Aspirin Therapy in COVID-19: Prevention of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2023)

Statin Therapy in COVID-19: Inhibition of NETosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Role of frailty in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2022)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
por: Kow, Chia Siang, et al.
Publicado: (2020)

Association of frailty and mortality in patients with COVID-19: a meta-analysis
por: Kow, Chia S., et al.
Publicado: (2021)

Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Statin use in patients with diabetes amid COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Macrolides for patients with COVID-19 and concurrent pertussis infection
por: Kow, Chia Siang, et al.
Publicado: (2021)

Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2021)

The use of corticosteroids in patients with COVID-19 vaccine–related cerebral venous thrombosis
por: Kow, Chia Siang, et al.
Publicado: (2022)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Hyperbaric oxygen therapy to reverse post-COVID cognitive impairment
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Probiotics for the Prevention of COVID-19 Sequelae
por: KOW, CHIA SIANG, et al.
Publicado: (2022)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection
por: Isidori, Andrea M, et al.
Publicado: (2020)

Use of sulforaphane in COVID-19: Clinical trials are needed
por: Kow, Chia Siang, et al.
Publicado: (2022)

Can COVID-19 vaccines improve cardiovascular outcomes?
por: Kow, Chia Siang, et al.
Publicado: (2022)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Further discussion on glucocorticoid treatment of COVID-19
por: Feng, Yun’ai, et al.
Publicado: (2022)

Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021)

Renin–angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
por: Kow, Chia Siang, et al.
Publicado: (2021)

Should COVID-19 be considered cardiovascular disease risk equivalent?
por: Kow, Chia Siang, et al.
Publicado: (2023)

The effect of vitamin C on the risk of mortality in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
por: Kow, Chia Siang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2aqndt32rd84rbqu2kn6q8d92j